N-(2-n-Propylpentanoyl)-1-aminoindan | 168902-99-6

• 分子结构分类: 有机化合物 - 苯类化合物 - 茚满类
• 英文名称: N-(2-n-Propylpentanoyl)-1-aminoindan
• 英文别名: N-(2,3-dihydro-1H-inden-1-yl)-2-propylpentanamide
• CAS: 168902-99-6
• 化学式: C₁₇H₂₅NO
• 分子量: 259.392
• InChiKey: NXFYDRWQMRCJMY-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  4.8
• 重原子数：
  19
• 可旋转键数：
  6
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.59
• 拓扑面积：
  29.1
• 氢给体数：
  1
• 氢受体数：
  1

反应信息

• 作为反应物：
  描述：

  N-(2-n-Propylpentanoyl)-1-aminoindan 在 氯磺酸 、 ammonium hydroxide 作用下， 以 四氢呋喃 为溶剂， 反应 2.0h， 生成 2-propyl-N-(5-sulfamoyl-2,3-dihydro-1H-inden-1-yl)pentanamide
  参考文献：
  名称：

  Indanesulfonamides as Carbonic Anhydrase Inhibitors. Toward Structure-Based Design of Selective Inhibitors of the Tumor-Associated Isozyme CA IX

  摘要：

  Carbonic anhydrases are ubiquitous metalloenzymes which are involved in fundamental processes (i.e., acid-base regulation, respiration, calcification, etc.). The carbonic anhydrase isozyme IX becomes an interesting pharmacological target due to its overexpression in cancer and its absence in normal tissue. Therefore, several indanesulfonamides were synthesized and tested for their inhibition both against the human CA IX and against two other biologically relevant isozymes (CA I and II). Structure-activity relationships are discussed and point out different compounds for its selectivity and activity against CA IX. To establish preliminary hypothesis for the design of new isozyme-selective CA IX inhibitors, we conducted molecular modeling. We describe here the first human CA IX model built by homology with another CA isozyme already crystallized. Docking studies were performed to explore the binding mode of our indanesulfonamide derivatives.

  DOI：

  10.1021/jm0600287
• 作为产物：
  描述：

  丙戊酸 在 氯化亚砜 作用下， 以 氯仿 为溶剂， 反应 1.0h， 生成 N-(2-n-Propylpentanoyl)-1-aminoindan
  参考文献：
  名称：

  Indanesulfonamides as Carbonic Anhydrase Inhibitors. Toward Structure-Based Design of Selective Inhibitors of the Tumor-Associated Isozyme CA IX

  摘要：

  Carbonic anhydrases are ubiquitous metalloenzymes which are involved in fundamental processes (i.e., acid-base regulation, respiration, calcification, etc.). The carbonic anhydrase isozyme IX becomes an interesting pharmacological target due to its overexpression in cancer and its absence in normal tissue. Therefore, several indanesulfonamides were synthesized and tested for their inhibition both against the human CA IX and against two other biologically relevant isozymes (CA I and II). Structure-activity relationships are discussed and point out different compounds for its selectivity and activity against CA IX. To establish preliminary hypothesis for the design of new isozyme-selective CA IX inhibitors, we conducted molecular modeling. We describe here the first human CA IX model built by homology with another CA isozyme already crystallized. Docking studies were performed to explore the binding mode of our indanesulfonamide derivatives.

  DOI：

  10.1021/jm0600287

文献信息

• Method for preparing optically active 1-aminoindan derivatives
  申请人：Teva Pharmaceutical Industries, Ltd.

  公开号：US05639913A1

  公开（公告）日：1997-06-17

  Novel derivatives of 1-aminoindan and their salts are described. Optically active 1-aminoindan derivatives are prepared by reacting a N-benzyl analog of the desired compound with an enantiomer of mandelic acid. Parkinson's disease, dementia, epilepsy, convulsions, or seizures are treated by administering a compound of the formula: ##STR1##

  本文描述了1-氨基茚的新衍生物及其盐。通过将所需化合物的N-苄基类似物与曼德酸对映异构体反应制备了光学活性的1-氨基茚衍生物。通过给予下列式的化合物治疗帕金森病、痴呆症、癫痫、惊厥或癫痫发作：##STR1##
• COMPOSITIONS CONTAINING AND METHODS OF USING 1-AMINOINDAN AND DERIVATIVES THEREOF AND PROCESS FOR PREPARING OPTICALLY ACTIVE 1-AMINOINDAN DERIVATIVES
  申请人：——

  公开号：US20020068839A1

  公开（公告）日：2002-06-06

  Novel derivatives of 1-aminoindan and their salts are described. Optically active 1-aminoindan derivatives are prepared by reacting a N-benzyl analog of the desired compound with an enantiomer of mandelic acid. Parkinson's disease, dementia, epilepsy, convulsions, or seizures are treated by administering a compound of the formula: 1

  描述了1-氨基茚的新衍生物及其盐。通过将所需化合物的N-苯甲基类似物与苯丙酸对映异构体反应制备了光学活性的1-氨基茚衍生物。通过给予公式1的化合物治疗帕金森病、痴呆症、癫痫、惊厥或抽搐。
• Compositions containing and methods of using 1-aminoindan and
  申请人：Teva Pharmaceutical Industries, Ltd.

  公开号：US05994408A1

  公开（公告）日：1999-11-30

  Novel derivatives of 1-aminoindan and their salts are described. Optically active 1-aminoindan derivatives are prepared by reacting a N-benzyl analog of the desired compound with an enantiomer of mandelic acid. Parkinson's disease, dementia, epilepsy, convulsions, or seizures are treated by administering a compound of the formula: ##STR1##

  本发明描述了1-氨基茚的新衍生物及其盐。通过将所需化合物的N-苄基类似物与苯乙酸对映异构体反应制备出光学活性的1-氨基茚衍生物。通过给予公式如下的化合物治疗帕金森病、痴呆症、癫痫、惊厥或抽搐：##STR1##
• Compositions containing and methods of using 1-aminoindan and derivatives thereof and process for preparing optically active 1-aminoindan derivatives
  申请人：Teva Pharmaceutical Industries, Ltd.

  公开号：US06271263B1

  公开（公告）日：2001-08-07

  Novel derivatives of 1-aminoindan and their salts are described. Optically active 1-aminoindan derivatives are prepared by reacting a N-benzyl analog of the desired compound with an enantiomer of mandelic acid. Parkinson's disease, dementia, epilepsy, convulsions, or seizures are treated by administering a compound of the formula:

  本文描述了1-氨基茚的新型衍生物及其盐。通过将所需化合物的N-苄基类似物与苯乙酸对映异构体反应，制备了光学活性的1-氨基茚衍生物。通过给患者施用公式化合物治疗帕金森病、痴呆、癫痫、惊厥或抽搐。
• 1-AMINOINDAN DERIVATIVES AND COMPOSITIONS THEREOF
  申请人：TEVA PHARMACEUTICAL INDUSTRIES, LTD.

  公开号：EP0738149A1

  公开（公告）日：1996-10-23